Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.15, $0.06 better than the analyst estimate of $0.09. Revenue for the quarter came in at $52.4 million versus the consensus estimate of $50.75 million.

GUIDANCE:

Puma Biotech sees Q3 2025 revenue of $48-51 million, versus the consensus of $57.5 million.

Puma Biotech sees FY2025 revenue of $212-222 million, versus the consensus of $220 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.